Identification of Wnt/β-Catenin- and Autophagy-Related lncRNA Signature for Predicting Immune Efficacy in Pancreatic Adenocarcinoma

Lyu, Hao; Zhang, Jiahui; Qian, Wei; Huang, Yuan; Zhang, Rui; Xiao, Shuai; Guo, Dong; Chen, Xing-Zhen; Zhou, Cefan; Tang, Jingfeng

doi:10.3390/biology12020319

Cited by 5 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings suggest that DKK1 may affect the immune status of the tumor in OSCC via the regulation of specific immune checkpoint genes. Notably, DKK1 is an inhibitor of Wnt signaling, which can affect the tumor immune status in various types of tumor (36)(37)(38). However, studies on the relationship between Wnt signaling and the DKK1-related immune checkpoint genes screened in the present study are lacking.…”

Section: Discussionmentioning

confidence: 84%

Role of prognostic gene DKK1 in oral squamous cell carcinoma

Liu,

Wei,

Wang

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is one of the most common squamous cell carcinomas of the head and neck. The morbidity and mortality rates of OSCC have increased in recent years. However, the pathogenesis of this disease remains unknown. The present study aimed to identify predictive biomarkers and therapeutic targets for OSCC. Bioinformatics screening of differentially expressed genes in OSCC was performed based on data from The Cancer Genome Atlas and Gene Expression Omnibus databases. Dickkopf Wnt signaling pathway inhibitor 1 (DKK1) was identified to be associated with survival, tumor immunity and DNA repair in OSCC. Furthermore, the effects of DKK1 were evaluated by the knockdown of DKK1 in two OSCC cell lines. The proliferation, clonogenicity, migration and invasion of the cells were assessed in vitro using Cell Counting Kit-8, colony formation, wound healing and Transwell assays, respectively, and were found to be inhibited by DKK1 knockdown. The present study suggests that DKK1 may be used in the prognosis of patients with OSCC and that targeting DKK1 is a potential strategy for OSCC therapy.

show abstract

Section: Discussionmentioning

confidence: 84%

Role of prognostic gene DKK1 in oral squamous cell carcinoma

Liu,

Wei,

Wang

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…In accordance with our data for EOC, high expression levels of GUSBP11 are predicted to bind miR-22-3p to avoid CCN2A mRNA degradation, correlating to poor overall survival in hepatocellular carcinoma patients [ 81 ]. Conversely, GUSBP11 expression correlates with better prognosis in head and neck squamous cell carcinoma [ 82 ], bladder cancer [ 83 ], papillary renal cell carcinoma [ 84 ], and pancreatic adenocarcinoma [ 85 ]. Regarding MIR924HG , there is no information about it in the literature.…”

Section: Discussionmentioning

confidence: 99%

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

Salamini-Montemurri

Lamas-Maceiras

Lorenzo-Catoira

et al. 2023

IJMS

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is one of the deadliest gynecological cancers worldwide, mainly because of its initially asymptomatic nature and consequently late diagnosis. Long non-coding RNAs (lncRNA) are non-coding transcripts of more than 200 nucleotides, whose deregulation is involved in pathologies such as EOC, and are therefore envisaged as future biomarkers. We present a meta-analysis of available gene expression profiling (microarray and RNA sequencing) studies from EOC patients to identify lncRNA genes with diagnostic and prognostic value. In this meta-analysis, we include 46 independent cohorts, along with available expression profiling data from EOC cell lines. Differential expression analyses were conducted to identify those lncRNAs that are deregulated in (i) EOC versus healthy ovary tissue, (ii) unfavorable versus more favorable prognosis, (iii) metastatic versus primary tumors, (iv) chemoresistant versus chemosensitive EOC, and (v) correlation to specific histological subtypes of EOC. From the results of this meta-analysis, we established a panel of lncRNAs that are highly correlated with EOC. The panel includes several lncRNAs that are already known and even functionally characterized in EOC, but also lncRNAs that have not been previously correlated with this cancer, and which are discussed in relation to their putative role in EOC and their potential use as clinically relevant tools.

show abstract

“…However, the role of ncRNAs in the regulation of the Wnt/β-catenin pathway and autophagy has not been deciphered in the context of immune modulation. In this regard, a recent study has predicted six lncRNAs associated with the Wnt/β-catenin pathway and autophagy, which correlated with immune response in PDAC [ 210 ]. Particularly, this lncRNAs signature correlated with high CD8 + T cell and M0 macrophage infiltration in the tumors of the low-risk group, suggesting its high prognostic significance.…”

Section: Immunosuppression In Metastatic Pdacmentioning

confidence: 99%

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma

Gautam¹,

Batra²,

Jain³

2023

Mol Cancer

View full text Add to dashboard Cite

Immunosuppression is a hallmark of pancreatic ductal adenocarcinoma (PDAC), contributing to early metastasis and poor patient survival. Compared to the localized tumors, current standard-of-care therapies have failed to improve the survival of patients with metastatic PDAC, that necessecitates exploration of novel therapeutic approaches. While immunotherapies such as immune checkpoint blockade (ICB) and therapeutic vaccines have emerged as promising treatment modalities in certain cancers, limited responses have been achieved in PDAC. Therefore, specific mechanisms regulating the poor response to immunotherapy must be explored. The immunosuppressive microenvironment driven by oncogenic mutations, tumor secretome, non-coding RNAs, and tumor microbiome persists throughout PDAC progression, allowing neoplastic cells to grow locally and metastasize distantly. The metastatic cells escaping the host immune surveillance are unique in molecular, immunological, and metabolic characteristics. Following chemokine and exosomal guidance, these cells metastasize to the organ-specific pre-metastatic niches (PMNs) constituted by local resident cells, stromal fibroblasts, and suppressive immune cells, such as the metastasis-associated macrophages, neutrophils, and myeloid-derived suppressor cells. The metastatic immune microenvironment differs from primary tumors in stromal and immune cell composition, functionality, and metabolism. Thus far, multiple molecular and metabolic pathways, distinct from primary tumors, have been identified that dampen immune effector functions, confounding the immunotherapy response in metastatic PDAC. This review describes major immunoregulatory pathways that contribute to the metastatic progression and limit immunotherapy outcomes in PDAC. Overall, we highlight the therapeutic vulnerabilities attributable to immunosuppressive factors and discuss whether targeting these molecular and immunological “hot spots” could improve the outcomes of PDAC immunotherapies.

show abstract

Identification of Wnt/β-Catenin- and Autophagy-Related lncRNA Signature for Predicting Immune Efficacy in Pancreatic Adenocarcinoma

Cited by 5 publications

References 52 publications

Role of prognostic gene DKK1 in oral squamous cell carcinoma

Role of prognostic gene DKK1 in oral squamous cell carcinoma

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About